Roivant Sciences Financials - Benzinga

Roivant Sciences Ltd

ROIVNASDAQ

Trade with Public

Trade with Public

$36.50

-0.48-1.3%

가까이에: Sep 28, 5:00 PM EST

$36.75

-0.23-0.62%

프리마켓: 6:34 AM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Roivant Sciences Financials

Roivant Sciences (ROIV) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate

Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 36 percent decrease over losses of $(0.25) per share from

Benzinga Newsdesk

S&P 500 Rebounds Ahead Of Nvidia's Print, Oil Sinks 5% On Iran Truce Hopes: Stock Market Today

U.S. stocks halt a three-day slide as oil tumbles 5% on revived Iran truce hopes, easing inflation fears ahead of Nvidia's results after the close.

Piero Cingari

Earnings Scheduled For May 20, 2026

Benzinga Insights

PRO
Roivant Sciences Q4 Adj. EPS $(0.27) Beats $(0.34) Estimate

Benzinga Newsdesk

PRO
Roivant Sciences Q4 Sales $2.520M Miss $3.820M Estimate

Benzinga Newsdesk

Roivant Stock Soars On Experimental Skin Drug Delivering 100% Response - Why It Matters

Roivant shares surged after its skin disease drug brepocitinib showed strong Phase 2 results, with high response rates, early benefits, and no serious safety issues.

Vandana Singh

© 2026 Benzinga | All Rights Reserved